文献速递艾滋病与性传播感染

撒哈拉以南非洲地区换用含多替拉韦抗逆转录病毒治疗前的病毒载量状态与HIV治疗结局的关联

Viral Load Status Before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations With Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa.
PubMed 文献 · Clin Infect Dis · 2022-01-01

研究纳入撒哈拉以南非洲5国37个中心36393例换用含多替拉韦方案的患者,中位随访约11个月。与换药前病毒载量<200拷贝/mL者相比,无近期病毒载量检测或换药前病毒载量≥1000拷贝/mL者后续病毒载量≥1000拷贝/mL及肺结核或WHO临床4期事件的风险显著升高。作者认为换药前病毒载量检测可能有助于识别需要额外监测和/或依从性支持的患者。

要点

  • 换药前无近期病毒载量检测者后续病毒载量≥1000拷贝/mL的校正风险比为2.89。
  • 换药前病毒载量≥1000拷贝/mL者后续病毒载量≥1000拷贝/mL的校正风险比为6.60。
  • 换药前无近期检测或病毒载量≥1000拷贝/mL者肺结核或WHO临床4期事件风险显著升高。

核心结论

  • 换用多替拉韦前进行病毒载量检测可能有助于识别需要额外临床监测和/或依从性支持的患者。
  • 需要对换药时病毒载量未知或未抑制的患者进行进一步监测。

研究设计与样本

  • 国际流行病学艾滋病评估数据库联盟(IeDEA)的多国队列研究。
  • 纳入2017年7月至2020年2月期间从含奈韦拉平或依非韦伦方案换用含多替拉韦方案的患者,共36393例,来自5个国家(刚果民主共和国、肯尼亚、卢旺达、坦桑尼亚、乌干达)的37个中心,中位随访约11个月。
  • 采用多变量病因特异性风险回归分析换药前12个月内最近一次病毒载量检测与后续结局的关联。

主要发现

  • 与换药前病毒载量<200拷贝/mL者相比,无近期病毒载量检测者后续病毒载量≥1000拷贝/mL的校正风险比为2.89(95%CI 1.99-4.19)。
  • 与换药前病毒载量<200拷贝/mL者相比,换药前病毒载量≥1000拷贝/mL者后续病毒载量≥1000拷贝/mL的校正风险比为6.60(95%CI 4.36-9.99)。
  • 与换药前病毒载量<200拷贝/mL者相比,无近期病毒载量检测者肺结核或WHO临床4期事件的校正风险比为4.78(95%CI 2.77-8.24)。
  • 与换药前病毒载量<200拷贝/mL者相比,换药前病毒载量≥1000拷贝/mL者肺结核或WHO临床4期事件的校正风险比为13.97(95%CI 6.62-29.50)。

临床怎么用

  • 作者认为换用多替拉韦前进行病毒载量检测可能有助于识别需要额外临床监测和/或依从性支持的患者。
  • 作者提出需要对换药时病毒载量未知或未抑制的患者进行进一步监测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dolutegravir is being rolled out globally as part of preferred antiretroviral therapy (ART) regimens, including among treatment-experienced patients. The role of viral load (VL) testing before switching patients already on ART to a dolutegravir-containing regimen is less clear in real-world settings. METHODS: We included patients from the International epidemiology Databases to Evaluate AIDS consortium who switched from a nevirapine- or efavirenz-containing regimen to one with dolutegravir. We used multivariable cause-specific hazards regression to estimate the association of the most recent VL test in the 12 months before switching with subsequent outcomes. RESULTS: We included 36 393 patients at 37 sites in 5 countries (Democratic Republic of the Congo, Kenya, Rwanda, Tanzania, Uganda) who switched to dolutegravir from July 2017 through February 2020, with a median follow-up of approximately 11 months. Compared with those who switched with a VL <200 copies/mL, patients without a recent VL test or with a preswitch VL ≥1000 copies/mL had significantly increased hazards of an incident VL ≥1000 copies/mL (adjusted hazard ratio [aHR], 2.89; 95% confidence interval [CI], 1.99-4.19 and aHR, 6.60; 95% CI, 4.36-9.99, respectively) and pulmonary tuberculosis or a World Health Organization clinical stage 4 event (aHR, 4.78; 95% CI, 2.77-8.24 and aHR, 13.97; 95% CI, 6.62-29.50, respectively). CONCLUSIONS: A VL test before switching to dolutegravir may help identify patients who need additional clinical monitoring and/or adherence support. Further surveillance of patients who switched to dolutegravir with an unknown or unsuppressed VL is needed.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Romo ML, Edwards JK, Semeere AS, et al. Viral Load Status Before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations With Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa. Clin Infect Dis. 2022. PMID: 34893813. doi:10.1093/cid/ciab1006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。